Welcome to our dedicated page for Aldeyra Therapeutics SEC filings (Ticker: ALDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Aldeyra Therapeutics SEC filings document a biotechnology issuer focused on investigational therapies for immune-mediated diseases and formal disclosures tied to its RASP modulator pipeline. Recent 8-K reports furnish press releases and corporate presentations covering reproxalap regulatory review, clinical and preclinical program updates, pipeline prioritization, and FDA-related disclosures for dry eye disease.
The filing record also covers governance and capital-structure matters, including definitive proxy materials for annual meeting proposals and director elections, board-transition disclosures, and the payoff and termination of the Hercules Credit Facility. These filings group Aldeyra's public-company record around operating updates, risk and forward-looking-statement disclosures, stockholder voting matters, and financing arrangements.
Aldeyra Therapeutics, Inc. amendment to a Schedule 13G discloses that Perceptive Advisors LLC, Joseph Edelman and Perceptive Life Sciences Master Fund, Ltd. report 0% beneficial ownership of Aldeyra Therapeutics common stock (CUSIP 01438T106). The filing states each Reporting Person holds zero shares and confirms ownership of 5% or less of the class.
Aldeyra Therapeutics filed an update highlighting FDA feedback on its lead RASP modulator reproxalap, an AbbVie option agreement, and progress across its immunology pipeline. The FDA issued a Complete Response Letter for reproxalap in dry eye disease, citing lack of substantial efficacy evidence and inconsistent trial results, though no safety or manufacturing issues were identified and a Type A meeting is expected in the second quarter of 2026.
The company argues pooled trial data show a clear pattern of reproxalap superiority over vehicle and notes that five of nine efficacy trials met all primary endpoints, with P values below 0.05 for nine of 14 endpoints. Aldeyra also emphasizes strong Phase 3 data in allergic conjunctivitis and multiple early‑stage RASP modulators, rare retinal disease candidate ADX‑2191, and other programs. As of 12/31/2026, cash, cash equivalents, and marketable securities were $70, which Aldeyra believes will be sufficient to fund the company into 2028.
Aldeyra Therapeutics is holding its 2026 annual stockholder meeting on June 9, 2026 at 9:00 a.m. in Boston. Investors will vote on electing CEO Todd C. Brady as the sole Class III director, ratifying BDO USA, P.C. as auditor for 2026, and approving an advisory say-on-pay resolution.
BDO has audited Aldeyra since 2013 and received audit fees of $522,184 in 2025. For 2025, Brady’s compensation totaled $4.7 million, including $700,000 salary, a $189,000 bonus, and option awards valued at $3.8 million. For 2026, his salary is set at $750,000 with a $450,000 target bonus and significant new equity and cash-based awards.
The board is staggered into three classes and is majority independent, with separate chair and CEO roles and established audit, compensation, and nominating/governance committees. Directors receive cash retainers and stock options under a defined non-employee director compensation plan, and Aldeyra has adopted a clawback policy and insider trading restrictions.
Aldeyra Therapeutics, Inc. reported that Board member Martin J. Joyce has decided not to stand for re-election at the company’s 2026 annual meeting of stockholders. He will continue to serve as a director until his term expires at that meeting.
The company stated that Mr. Joyce’s decision was not the result of any disagreement with Aldeyra, indicating an orderly and voluntary board transition rather than a dispute-driven departure.
Aldeyra Therapeutics, Inc. has fully repaid its debt under the Hercules Credit Facility. On April 1, 2026, the company paid off outstanding borrowings of $15 million, and all remaining commitments under the loan agreement were terminated in line with its April 1, 2026 maturity.
The Hercules Credit Facility, originally entered in March 2019, is now fully closed. The company notes that its cash, cash equivalents, and marketable securities as of December 31, 2025 are expected to support operations into 2028, indicating sufficient liquidity after the loan repayment.
Aldeyra Therapeutics, Inc. President and CEO Todd C. Brady received new equity-based compensation awards. He was granted a stock option covering 1,880,510 shares of common stock at an exercise price of $1.77 per share. This option vests in equal monthly installments over 48 months of continuous service after January 1, 2026 and expires on March 26, 2036.
Brady was also awarded 632,318 bonus units, which vest in equal annual installments over four years beginning on March 27, 2026, contingent on continued service. Each vested bonus unit entitles him to a cash payment equal to the closing price per share of Aldeyra’s common stock on the payment date, made on the earlier of four years from grant or a Change of Control. These are compensation grants, not open-market share purchases or sales.
Aldeyra Therapeutics Inc ownership disclosure: The Vanguard Group amended its Schedule 13G to report 0 shares beneficially owned, representing 0% of the Common Stock as disclosed in the amendment.
The filing states Vanguard completed an internal realignment on January 12, 2026 and, "in accordance with SEC Release No. 34-39538 (January 12, 1998)", certain subsidiaries will report ownership separately.
Aldeyra Therapeutics director Richard Douglas bought more company stock in the open market. He acquired 70,000 shares of common stock in an open-market purchase at $1.40 per share. Following this transaction, he directly owns 195,000 shares, indicating a larger personal stake in Aldeyra Therapeutics.